Home page |Editorial  board | About the Journal   | Instructions for Authors | Peer Review Policy | Clinical and Experimental Work Code |   Contact  |

 

Acta Medica Medianae
Vol. 41
No 5, 2002
UDK 61
YU ISSN 0365-4478

 




Contact:
Radmila Veličković-Radovanović
Institute for Nephrology and Hemodialysis of the Clinic Center, Nis


 

 

FLUVASTATINE EFFICIENCV IN TREATING DVSLIPIDEMIA

IN THE PATIENTS AT THE PERITONEAL DIALYSIS

 

Radmila Veličković-Radovanović, Marina Avramović, Branka Mitić, Svetislav Kostić, Vidojko Đorđević and Miomir Stojanović

 

Institute for Nephrology and Hemodialysis of the Clinic Center, Nis

 

The pharmacotherapeutic attitude that the statins are optimal hypo-lipemic medicaments in treating the increased serum cholesterol is generally accepted. Regarding the fact that in the lipid profile of the patients with the terminal kidney inefficiency the hypercholesterolemia dominates at the peritoneal dialysis, the therapeutic efficiency and the fluvastatin forbearance are examined.

In the study the one-way blind, placebo controlled method of the clinic examination is used in the study. The research is carried out at the Institute for Nephrology and Hemodialysis of the Clinic Center, Nis, in 30 patients at the CAPD (14 men and 16 women, of average age 52,811,23 and dialyzing duration of 2,260,95 years). The patients are treated with fluvastatin, namely, 20 mg once a day, in the evening, for 6 months. The control placebo group was made up of 20 patients at the CAPD with similar clinic characteristics. The lipid status also comprised determination and monitoring of cholesterol (C), triglyceride (TG), lipoproteins of high density (HDL) and lipoprotein of small density (LDL).

During the six months of its application, fluvastatin has led to a statistically considerably important reduction of cholesterol (p 0,001), LDL (p<0,001) and Tg (p<0,05) along with a considerable increase of the HDL cholesterol (p<0,05). In the placebo group no considerable difference of the lipid parameters was noticed during the examination period. The gastric and the system tolerance of fluvastatin was good. Of the undesired effects, there was nausea and queasiness in 10 of the patients but this did not require the treatment to stop.

On the basis of the examination it is possible to conclude that fluvastatin has shown good therapeutic efficiency and tolerance in treating hyperlipidemia in the patients at the CAPD.

 

Key words: Fluvastatin, hyperlipidemia, peritoneal dialysis